Amnestic MCI Patients’ Perspectives toward Disclosure of Amyloid PET Results in a Research Context by Gwendolien Vanderschaeghe et al.
ORIGINAL PAPER
Amnestic MCI Patients’ Perspectives toward Disclosure
of Amyloid PET Results in a Research Context
Gwendolien Vanderschaeghe & Jolien Schaeverbeke &
Rik Vandenberghe & Kris Dierickx
Received: 10 January 2017 /Accepted: 3 March 2017
# The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract
Background Researchers currently are not obligated to
share individual research results (IRR) with participants.
This non-disclosure policy has been challenged on the
basis of participants’ rights to be aware and in control of
their personal medical information. Here, we deter-
mined how patients view disclosure of research PET
results of brain amyloid and why they believe it is
advantageous or disadvantageous to disclose.
Method As a part of a larger diagnostic trial, we con-
ducted semi-structured interviews with patients with
amnestic Mild Cognitive Impairment (aMCI). Partici-
pants had the option to receive their brain amyloid PET
scan result (i.e., their IRR). Interviews were conducted
before they received their IRR.
Results A total of 38 aMCI patients (100% of study
participants) wanted to know their IRR. The two most
frequently mentioned reasons for choosing IRR disclo-
sure were to better understand their brain health status
and to be better able to make informed decisions about
future personal arrangements (e.g., inheritance tax,
moving into a smaller house, end-of-life decisions,
etc.). Emotional risk was mentioned as the primary
disadvantage of knowing one’s IRR. On the other hand,
non-disclosure was considered to be emotionally diffi-
cult also, as patients would be uncertain about their
future health condition.
Conclusions Many patients diagnosed clinically with
aMCI want to know their brain amyloid test results,
even though this knowledge may be disadvantageous
to them. Knowing what is going on with their health and
the ability to make informed decisions about their future
were the two principal advantages mentioned for
obtaining their amyloid PET results. Because of the
overwhelming consensus of aMCI patients was to dis-
close their brain amyloid PET scan results, researchers
should strongly consider releasing this information to
research subjects.
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Background
Biomarkers are biological indicators that can gauge the
presence of a disease and can be used to support clinical
diagnosis [1]. One of the biomarkers used to support a
diagnosis of Alzheimer’s Disease (AD) is based on brain
amyloid, which can be visualized in situ by positron
emission tomography (PET) and radiotracers that have a
high affinity for binding to beta-amyloid plaques
in vivo. PET imaging of beta-amyloid plaques in the
brain has been approved for diagnostic purposes in
cognitively impaired patients who are being evaluated
for AD [2, 3]. Besides being useful for clinical situa-
tions, PET imaging of beta-amyloid plaques is also
being used in brain research on AD.
Little is known about patients’ motivations, opinions,
and experiences in relation to their clinical trial participa-
tion and their IRR. In a research context, the degree to
which individual research results (IRR) are shared with
study participants varies, as the researcher is not obligated
to do so [3, 4]. Reasons to support the non-disclosure
policy mostly relate to differences between the research
and clinical context, the limited efficacy of current treat-
ments, the experimental nature of certain types of data, and
the limitations of lay participants to objectively and rea-
sonably interpret the results [5, 6]. On the other hand, some
reasons to support IRR disclosure are the right of partici-
pants to know and be in control of information about their
medical condition, it affords participants the opportunity to
make informed lifestyle changes and practical personal
and family arrangements, and it opens up the possibility
for participants to enroll in (early)medical interventions [5,
7, 8]. The previously mentioned reasons are based on the
available theoretical literature and are mostly used by
researchers to support or withhold IRR disclosure. Yet,
what are the concrete reasons and motivations of research
participants? Thus, the following questions arise. Why
would participants opt for the possibility to be informed
about their IRR?What do participants perceive as possible
advantages and disadvantages of knowing their IRR?
Clear answers to these questions will help guide re-
searchers and experimental subjects in deciding which
option—IRR disclosure or non-disclosure—to choose.
In this study, we focused on the reasons why patients
with amnestic mild cognitive impairment (aMCI) were
either in favor of or against the disclosure of their brain
amyloid PET results. The experiences and opinions of
these aMCI patients can differ from those of healthy
individuals being screened for AD [9]. We also focused
on the disclosure of brain amyloid PET scan results,
because these biomarker findings have been approved
by the FDA (Food and Drug Administration) and EMA
(European Medicines Agency) for clinical use in pa-
tients with a cognitive deficit [10–12]. Our findings




Recruitment took place between June 2015 and
June 2016 after approval of the study by the Ethics
Committee, University Hospitals Leuven. All partici-
pants provided written informed consent in accordance
with the Declaration of Helsinki.
The study cohort consisted of a consecutive series of
aMCI patients [13] recruited via the memory clinic of
the University Hospitals Leuven. The interviewwas part
of a sub-study of the BioAdaptAD study, an
investigator-driven longitudinal study of aMCI. The pri-
mary objective of the BioAdaptAD study (EUDRACT
no. 2013–004671-12) was to evaluate the predictive
value of baseline amyloid biomarker measurements for
tracking longitudinal cognitive change over a two-year
period. When candidate subjects met the inclusion
criteria (see Appendix 1) of the BioAdaptAD study, they
were given the option to participate in a sub-study in-
vestigating the opportunities to receive their IRR and the
ethical challenges associated with it. More specifically,
this sub-study provided the participants with the option
of receiving their amyloid PET scan (binary visual read
or positive/negative for brain amyloid) results that were
obtained within the context of the BioAdaptAD study.
We conducted semi-structured interviews with partici-
pants who agreed to take part in the sub-study in order to
better understand their motivations, opinions, and expe-
riences about the disclosure of their IRR.
Before the start of the sub-study, an informed consent
brochure was given to candidate subjects. The content of
this brochure was based on the E6 Guideline of Good
Clinical Practice and contained background information
about the study, study objectives, the interview process,
and research subjects’ rights. Before the scheduled in-
terview, the interviewer orally repeated the content of the
informed consent brochure and asked the candidate
whether they had any further questions. If they hesitated
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or had doubts about participating, the interview was re-
scheduled to a later time to give the candidate sufficient
time to decide.
Data Collection and Analysis
The interview guide was developed byGV, KD, and RV,
and its content was based on findings in the literature on
the topic of IRR. The first two interviews constituted a
pilot study, which was used to evaluate the interview
guide and make needed adjustments. The interview
questions covered three content areas. The first part of
the interview consisted of questions intended to help us
better understand how patients describe and experience
their current memory problems. Although patients’ de-
scription of their memory complaints were not intended
to be part of the result section of this manuscript, these
exploratory questions were used as opening questions
for the interview and to provide the interviewer with
some concrete patients’ experiences regarding their
memory complaints. The second part consisted of
open-ended questions about why they want to know
their IRR result and what they perceive as possible
(dis)advantages of their IRR disclosure. The third part
consisted of hypothetical questions about how the pa-
tient thinks he would respond to a set of possible situa-
tions, such as: ‘What if the researcher informs you that
you have a positive amyloid PET scan result? How do
you think you will respond to this news? Several inter-
view techniques were used, such as rephrasing part of
the participant’s answer, asking yes or no questions, to
briefly check whether the interviewer understood the
participant’s answer correctly. Supplementary questions
were also asked to get more in-depth information from
the participant.
After a short introduction of what the research was all
about and what to expect in the interviews, patients were
invited to sign the informed consent form (IC) and then
to complete the sociodemographic information form.
Completion of the IC form indicated that the patient
understood that his/her results and interview records
would remain confidential, that participation in the in-
terview was voluntary, and that it would have no impact
on his/her participation in the general study or on any
other medical intervention he/she might undergo at the
hospital. Participants were informed that results of the
study would be published in a scientific journal and that
a lay description of results from the interviews would be
provided to them after completion of the study.
The interviews were recorded on tape with the consent
of the interviewee. A mixed-method approach was used
to analyze the interviews. (1) Transcripts were analyzed
using QSR International’s Nvivo 10 software and was
performed according to qualitative conventional content
analysis methodology [14, 15]. In the first phase, the
interviewer (GV) coded the interviews three separate
times, with an interval of a few weeks between each
coding session. Letting time pass between each session
and re-coding allows one to check whether new interpre-
tations might be attributed to the content that could have
been missed in just one coding session. To protect against
bias, in the second analysis phase, we had five interviews
independently coded by a second researcher. In the final
phase, we compared the codes assigned by the interview-
er and those done by the independent researcher (KD),
working to reach a consensus on the final codes to be
used. (2) In addition, we used a quantitative approach to
analyze the reasons, benefits, and disadvantages of re-
ceiving an IRR, as provided by the participants.
Interviews were conducted in Dutch, with the excep-
tion of one, which was conducted in English. For this
interview, the patient preferred to speak in his native
language, English. Quotations of patients presented here
have been translated into English.
Results
Study Population
The study population consisted of 38 aMCI patients who
met the inclusion criteria of the study. Table 1 summa-
rizes the demographic information and scores of the
neuropsychological evaluation of the study population.
Reasons forWanting to KnowBrain Amyloid PET Scan
Result (IRR)
The results presented here are based on participants’
answers in the interview before receiving their IRR.
We decided to conduct the interviews in this order so
that we could get unbiased answers as to why patients
might want to know their IRR. All participants
expressed the desire to know their individual brain
amyloid PET scan result (i.e., IRR). Although one par-
ticipant initially did not want to know his IRR, after
thinking more about it, he changed his mind. Overall,
nine reasons were mentioned by the participants for
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wanting to know their IRR. Some participants men-
tioned two or three reasons (Fig. 1). These reasons will
be considered in turn and elaborations will be provided
in participants’ quotes.
* Some participants mentioned more than one
reason.
(1) The patient’s right to know their personal medical
information was mentioned as one reason. As one
participant described it, BI think I have that right. It
is from me; it is my body. And I know that I would
rather know, otherwise it is useless to participate, I
think [...]^ (Woman, 63 years old). This reason
was the least frequently mentioned.
(2) Another reasonmentionedwas that participants were
simply curious. One participant indicated that he was
fascinated but did not elaborate on what he found
interesting or fascinating about knowing his IRR.
(3) Another reason participants mentioned was that
some had one or more family member(s) with de-
mentia or who were diagnosed with AD. Since they
had witnessed relatives who had AD, they knew
firsthand what the disease does to a person, and this
motivated them to volunteer for the study and to opt
in for receiving their IRR. This reason was men-
tioned more frequently than the first two reasons.
(4) The fourth reason was to get information so that
they could Inform others about their current health
situation and discuss with them how their health
might change in the near future. Participants most-
ly referred to their partner, children, relatives, or
sometimes the close environment, like their neigh-
bors, as Bothers.^ Participants viewed this reason
for wanting to know their IRR as being an advan-
tage. This aspect of knowing one’s IRR will be
discussed more in a subsequent section.
(5) Not knowing what was going on led to certain doubts,
questions, and sometimes even anger, when forgetting
something repeatedly. They hoped that getting their
IRR would ease their mind, helping them to regain
their composure and not get so visibly upset. This
reason was mentioned as frequently as reasons 3 and
4 for wanting to know their IRR.
(6) Five participants mentioned that they considered it
a better option to receive the possibly bad
Bnews^ contained in their IRR at an early,
beginning stage of a disease than to receive
it at a later, advanced stage.
(7) One of the most frequently mentioned reasons for
participants desiring to know their IRR related to
possible treatments (Fig. 1). That is, if they knew
their IRR, they might be able to make better
choices about treatments for the symptoms they
were experiencing. Treatment was described in
two ways. On the one hand, participants talked
about medication that might slow down the pro-
gression of the disease and thus possibly prolong
their quality of life. On the other hand, they re-
ferred to treatment as making renewed health-
related lifestyle changes. For example, a partici-
pant said that he would stop his weekly habit
of drinking a pint of beer, and another partic-
ipant was considering taking food supple-
ments, if this was recommended by clinicians
to treat their symptoms.
(8) Making informed future life decisions was the
most frequently given reason for wanting to know
one’s IRR. Participants referred to the opportunity
of making arrangements or planning for the future,
as they wanted to arrange their affairs before their
Table 1 Demographic Characteristics and neuropsychological
evaluation scores of the study population of aMCI patients
Characteristics n = number
Mean age:














Neuropsychological evaluation Mean score
Global Clinical Dementia Rating (CDR) 0.5
Mini Mental State Examination (MMSE) 27.8 (range: 25–30)
Auditory Verbal Learning Test
(AVLT) Total Learning (/75)
36.2 + − 10.2
AVLT long term % recall 61.7% + − 29.6%
Vanderschaeghe G. et al.
memory problems became worse. Some participants
clearly indicated that they had always made their own
decisions, so they wanted to continue doing such, so
they could avoid becoming a burden to others. The
nature of this reasonwas diverse and could be divided
into five general topical areas (Fig. 2). These will be
considered in turn (a-e, below).
Topical area (a). This area was related to making
lodging accommodations. One participant men-
tioned how he was currently considering selling
his house and moving into a smaller house or
apartment.
Topical area (b). This area was related to
rearranging household tasks. Areas (a) and (b) were
mentioned equally as often.
Topical area (c). The importance of arranging for
elderly residential care in advance was another
topic related to making advanced arrangements.
One participant explained this by describing the
difficulties related to Bplacing^ or Bforcing^ elderly
people to go to an elderly care center against their
own wishes.
Topical area (d). Another given arrangement was to
make financial decisions, such as donations to
avoid inheritance taxes, or to find a person who
can help with finances when the patient is no longer
capable of caring for it by himself.
Topical area (e). The most frequently mentioned
topical area related to making arrangements about
euthanasia. Participants said this was mostly be-
cause they wanted to relieve the burden placed on
their partner and children for caring for them in a
demented condition. They also did not want Bto live
like a plant,^ as they often described it. While some
participants had already discussed this with their
partner, and sometimes with their children, some
participants stated that they would discuss this only
when the result was known. The participants who
had already talked about this felt understood and
supported by their partner and/or children. This was
nuanced in two different ways:
The first nuance related to a clarification that the
request for euthanasia was not just to relieve them
and their family of the consequences of AD, but also
for other diseases that are legally accepted condi-
tions according to the euthanasia law in Belgium.
The second nuance emerged from a statement by
another participant, who said that receiving a posi-
tive brain amyloid PET scan would not result in
panic and the immediate consideration of euthana-
sia. In addition, we noticed that most of the partic-
ipants were unaware of the explicit details of
Belgium’s Euthanasia law and the various types of
documents required for early care-planning and
end-of-life decisions. This lack of information re-
sulted in participants describing euthanasia in gen-
eral terms and referring to Bthe document^ without
further clarification. Only one participant clearly
described how he had all the necessary documents
ready, as he had already consulted the Levens Einde
Informatie Forum (LEIF).1 LEIF is a national forum
supported by the Belgian government concerning
end-of-life decisions and dignified dying. While
some participants had clear ideas about which spe-
cific arrangements they would make, other partici-
pants talked in general terms about making future
1 Translated as, BBefore You Go.^
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Know what is going on
Plan the future/arangements
Treatment
To know in an early stage
Composure
To inform others
Family member with AD
Out of interest
Right to know
Fig. 1 Frequency of reasons participants mentioned for wanting to know their brain amyloid PET scan result (i.e., IRR).*
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arrangements.When asked to elaborate, they did not
know yet which arrangements they would make.
(9) Finally, the most frequently mentioned reason of
our participants for desiring to know one’s IRR
was to be informed about what was going onwith
one’s health (Fig. 1). In this vein also, participants
often talked about future perspectives. If they
could know what was going on, then they might
know a little bit more about whether their symp-
toms could become worse or not.
Perceived Advantages of Knowing one’s IRR
While we wanted to better understand why participants
want to know their brain amyloid PET scan results, we
also wanted to know what advantages or benefits par-
ticipants perceived for IRR disclosure of brain amyloid
PET imaging.
A minority of participants pointed out that there were
no advantages, or at least none that they could not think
of, for knowing their IRR. A participant wondered more
specifically whether receiving a positive amyloid PET
scan result could be perceived as advantageous. As she
explained, B[…] will there be any advantages? That’s
the problem. If it is bad, is it actually, maybe disadvan-
tageous that I know it^ (Woman, 81 years old). The
majority of participants reflected on the advantages of
getting their IRR. Eight advantages were mentioned, as
indicated in Fig. 3. These will be considered in turn.
(1) Knowing the result implies that one can take stock
of one’s own capabilities and then determine what
is still possible to do or not to do, according to
one’s current health situation. Few participants
mentioned this advantage.
(2) Receiving the result yourself rather than a family
member, who may or may not disclose it. One
participant mentioned that if the result were
disclosed to her son, for example, she was afraid
that he might not give her the complete information.
When asked why this would be the case, she said
that her sonmight phrase the news in a softer way to
spare her emotionally. However, she wanted to
know her situation firsthand, not filtered through a
third party (e.g., caregiver or family member). That
is why she perceived this as an advantage, whereby
the researcher-neurologist would directly and
completely disclose the news to her.
(3) Participants said that it would be advantageous to
know the IRR at an early stage, so that they could
benefit from an early intervention of treatment or
imposition of health-related lifestyle changes. The
difference between this advantage and the advan-
tage of treatment (i.e., Advantage 7, below) is that
participants specifically referred to the benefit of
knowing this result at an early stage.
(4) Compared to just giving a reason for IRR disclo-
sure (i.e., previous section on informing others),
more participants mentioned Binforming others^ as
an advantage for knowing their IRR. While some
participants focused on just informing their partner
and children, other participants would also involve
close friends. The benefit of informing others
about their result is that they can take your new
situation into account in personal interactions. One
patient clearly indicated how she would tell her
partner and children, but not tell anyone else. She
explained, BNo, you often think that you have
friends, but behind your back […]. Nowadays,
people are so dastardly^ (Woman, 72 years old).
By contrast, one patient expressed that she was not
sure whether to inform her children, because she
Euthanasia
Financial arrangements
Elderly care or residential care…
Household tasks
Selling house, move to smaller place
Arrangements
Fig. 2 Frequencies of topical references made in relation to IRR affording the opportunity for making arrangements or planning for the future
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was afraid of hurting them. As she described it,
BYes, I don’t even know whether or not I would tell
that to my children. No, because that must be dev-
astating if they know that their mother within 5
years... Yes, I believe I would not say it^ (Woman,
63 years old). We have to be clear that she did not
refer to this aspect as an advantage or a disadvantage
for knowing her IRR. This contrasting reaction does
reveal how other participants can have different
motivations for choosing not to inform others.
(5) Some participants stated that with the knowledge of
their brain amyloid status they could enjoy life more.
For example, they could travel more and do the things
they had wanted to do in the past but had to postpone.
Although, it was not immediately clear for every
participant what he would enjoy in life more. They
thought this would become clear and more obvious
once they know the result. One participant already
started to enjoy lifemore since he started to experience
subtle memory complaints. As he described it:
BOn the contrary, if you know something, you be-
come more aware of this fact. Buddy, you need to
enjoy life more. You know what we did?We reserved
three city trips for this year. I found that; thank you,
Alzheimer [laughs] […]^ (Man, 68 years old).
(6) With new knowledge about their health, participants
felt doubt was removed about what was causing
their memory problems. A positive brain amyloid
test result implied for some that they had achieved
more clarity about their current situation:
B[…] An advantage is, I think personally, you are
with this in your mind [whether you have brain
changes leading to AD]; you doubt^ (Man, 66
years old).
Sometimes, one’s doubt is amplified when others
comment on your memory problems:
BI know that something is going on, but what? Is it
Alzheimer? Is it dementia? Or is this normal with
age? Yes, then they say: ‘Yes, but those people are
also so old and they know more.’ But I think that it
is not the same with everyone. I don’t know. It is a
big question mark for me, and that’s why I want to
know it^ (Woman, 68 years old).
For some patients, no result could even lead to them
losing composure, making them angry or frustrated
every time they forget something.
(7) The possibility of being eligible for treatment.
Patients did not only refer to treatment as a kind
of medication or lifestyle changes but also to the
advantageous consequences of receiving treat-
men t , spec i f i c a l l y fo l l ow-up med i c a l
consultations.
(8) The last advantage relates to being better prepared
to plan for the future and make personal arrange-
ments should they receive a positive result (Fig. 4).
Plan the future/arrangements
Treatment
Less doubt, more clarity
To enjoy life more
To inform others
Early stage disclosure
To receive the result yourself
To take your own capabilities into account
No advantages
Advantages of knowing 
the IRR
Fig. 3 Frequencies of perceived advantages of knowing the IRR by participants
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New practical arrangements were expressed by the
participants that were not mentioned earlier as reasons
for wanting to know their IRR. First, arranging for one’s
funeral or cremation was mentioned: BHow I want my
funeral or cremation and so on. These kind of things^
(Woman, 68 years old). Another participant referred to
making arrangements with their partner about creating
schedules and stable places to make life easier in case
her symptoms became worse. For example, she wanted
to arrange for a consistent place to leave her keys and
money. Another final arrangement one participant men-
tioned was finding appropriate care for her pets, as she is
currently living alone.
One participant had a different opinion of what sort of
future arrangements she should make if she knew her
IRR. Although she described making arrangements for
the future as being an advantage for knowing one’s
results, unlike other patients, euthanasia and arranging
her funeral were not included as part of her arrangements.
This example shows how patients can have different
ideas about what sorts of things to consider when plan-
ning for their future. For one patient, planning for one’s
funeral, for example, is an absolute necessity, while for
another patient, it is not so important. This sentiment is
reflected in the following quote from this woman:
BAnd yesterday, yes, that’s maybe, I don’t know, all
the children were there, and then I told them. So, if
the time comes that I have Alzheimer’s, and that they
will investigate now, then I don’t want euthanasia. I
have already told that to them. I want to stay in this
world. I don’t know if that is an unhappy world. My
mother [who had dementia] cried a lot. That won’t
be so easy. But still, I don’t want euthanasia. And
they can place me in the same department in that
elderly care house where my mother was. Like that
we talked about it. And yes, they didn’t seem sur-
prised. But now I won’t talk about it anymore. That
was that one time. But with that I know, because
death and arranging your funeral, that not, that I
won’t do^ (Woman, 63 years old).
In the previous section, participants talked about
requesting euthanasia because they did not want to
become a burden for their family or because they did
not want to live in a vegetative state. While this partic-
ipant indicated that having AD is most likely not an easy
thing to experience, she felt that having AD does not
necessarily mean that one would be living in an Bun-
happy world.^
Perceived Disadvantages of Knowing one’s IRR
Next, we sought to determine whether participants per-
ceived any disadvantages in knowing their IRR. Half of
the participants spontaneously stated that there were no
disadvantages related to receiving an IRR. Some indicat-
ed that disadvantages likely exist, but the advantages of
knowing the results outweigh all possible disadvantages.
Participants did bring up, however, five specific disad-
vantages associated with knowing one’s IRR (Fig. 5).
(1) One disadvantage had to do with the hereditability of
AD and how it would affect relatives. One participant
clarified this, stating that a positive test result could be
disadvantageous for her son. However, she also elab-
orated on this aspect, stating that it is always better to
know these things in advance.
Euthanasia
Financial arrangements
Selling house, move to smaller place






Fig. 4 Frequencies of arrangements related to advantages mentioned by participants
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(2) A second disadvantage was linked to one’s own
perception of memory loss. This notion is in line
with what another participant stated: Knowing the
results might be disadvantageous if your results are
worse than how you perceived your own subtle
memory complaints to be and to how you thought
your health situation was.
(3) A third disadvantage mentioned was that knowing
one’s results could limit one’s freedom to do certain
things, like drive a car, one activity that would likely
be disallowed. As one participant described it:
B[...] Or [that] you cannot drive the car anymore,
because they recently said: ‘Do you have troubles
with that?Do you sometimes forget your way?Don’t
you forget where you are? […] I can still do that, but
I would not drive to the South of Spain. […] I would,
but I don’t think my wife would like to drive with me
anymore [laughs]^ (Man, 67 years old).
Furthermore, this man indicated that if his driver’s
license were taken away, this would have serious impli-
cations for his and his wife’s mobility, and this would
force them to live somewhere else.
(4) The fear of regression was also perceived as a
disadvantage of knowing one’s IRR result. That
is, the fear you get when you receive a positive test
result, that your cognitive decline will become
worse. Not knowing how long it will take before
the progression will accelerate, leads to fear and
questions for these participants.
(5) A final disadvantage mentioned was the emotional
risk and impact of receiving an IRR. Participants used
phrases such as, Bto shed a tear, feeling worried, fear
and more frustration,^ to describe the emotional
impact of receiving a positive brain amyloid PET
IRR. For example, one participant described it as:
BOf course it would be a shock if you heard it: You’ve
got Alzheimer’s or the chance is very high that soon
you will develop Alzheimer’s^ (Man, 81 years old).
One participant also indicated that receiving this
news may lead to internal confrontation:
BWell, in a sense, if you don’t know what the result
is, then you don’t have to make any plans. Once
you know the result, then you always got the
personal, because you start to think: BWell, how
long, why, what can I do about this and this.^ So,
there is more stress and pressure than before
[getting the result]^ (Man, 66 years old).
Others indicated that it is never a pleasant thing to hear
bad news, but the only way to deal with this news is to
accept it and to move on with life. This last reaction
indicated that many participants were aware of the possible
emotional difficulties connected to knowing one’s IRR.
They expressed that they do feel capable of dealing with
this information (i.e., the IRR). Some participants provided
more subtle answers; for example, how knowing the result
can be simultaneously advantageous and disadvantageous:
B[...] The advantage is to know it, yes. If you know it, then
it is a disadvantage that you have to accept it as it is, that
you cannot say, yes, I don’t want to know^ (Woman,
55 years old). In addition, not knowing the news, can be
emotionally difficult too, as expressed by one participant:
BYes, it won’t be a pleasant thing […]. If it is bad,
then it is not fun. Then your world collapses; I
know that too, but, does that weigh up against
walking around at home and feeling bad, because
you forget everything, and it is not going anymore,
and you are plodding? Well, I don’t know it [...]^
(Woman, 67 years old).
Emotional risk
Fear of regression
Not allowed to do things anymore
Worse situation than initially thought
Positive result implications for heritability towards…
No disadvantages
Disadvantages of knowing the IRR
Fig. 5 Frequencies of perceived disadvantages of knowing your IRR by participants
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Although the news can be emotionally difficult, some
participants argued that it is still better to know the result
now at an early stage of the disease so one can
still take actions, from starting therapy to making
personal arrangements:
BYou have to, you have to be able to absorb that
information of course, but if you get that now,
preventive or early, you get that information next
year or within 5 years, that does not matter. Soon-
er or later, it will come out as positive so rather
sooner than later is better, because then you can
still do something about it^ (Man, 63 years old).
Participants’ Understanding of an Amyloid PET Scan
Result
Confusion about the Meaning of the IRR: a Positive Test
Result Means Good News, Right?
Throughout the interviews it was clear that the terminology
researchers used to label a positive or negative brain amy-
loid PET scan result sometimes confused participants. A
positive test result was perceived as good news by some
participants. In a similar way, a negative test result was
perceived by some patients as bad news. Rather than
indicating the presence or absence of amyloid, some par-
ticipants thought ‘positive’ or ‘negative’ referred to the
emotional valence attached to the IRR. To be clear, a
positive brain amyloid PET scan indicates the presence of
higher levels of amyloid than age-normal, and an increased
likelihood that the aMCI patient would progress to AD.
Limited Predictive Value
No participant spontaneously mentioned the limited pre-
dictive value of brain amyloid PETscans as a disadvantage
of knowing one’s IRR. We specifically asked participants
about this, how they thought about their IRR in terms of a
high or low probability of developing AD.We also related
this to the less-than-100% certainty of the result (i.e., risk
of false positive and false negative) and the uncertainty
about how the disease progression might occur.
Participants indicated that in medicine, it is not un-
common for clinicians to speak in terms of high or low
chances, or use terms of percentage risk. Some partici-
pants referred to familial breast cancer for context, in
which the clinician spoke of x-percentage of risk based
on family history of breast cancer, x-chance of relapse,
etc. In fact, participants often indicated that medicine
never uses terms of absolute certainty.
Overall, participants indicated that being told they
have a high chance of their current memory problems
being due to early AD was already perceived as infor-
mation they would like to receive, instead of knowing
nothing about their current condition. They referred to
possible advantages of knowing this result, such as the
possibility of early intervention and disease monitoring:
BI continue to say that the earlier something like
this disease is diagnosed, even if it is not 100
percent certain, it is still better that they do every-
thing to prevent it than to cure it afterwards^
(Man, 63 years old).
However, three subtleties were expressed in these
views. (a) Some participants mentioned that if one receives
the result about progressing towards AD, yet this process
turns to go slower than researchers expected it would, this
was perceived as a good thing. (b) A participant mentioned
that there could be a disadvantage with this type of result.
He described it: B[...] The danger could possibly exist that
you, of course, start with medication, while this was not
necessarily required. But I don’t know if I am estimating
that correctly^ (Man, 74 years old). (c) There was another
participant who clearly indicated that she would like her
result and her medical condition to be told as it is, without
the clinician Bbeating around the bush.^
Other participants thought differently about the limited
predictive value of this IRR. One participant indicated that
it is better not to think about the limited predictive value of
the result and to have a ‘wait-and-see’ attitude towards
what might unfold. Another participant felt that it was
better that the researchers did not speak in terms of 100%
certainty, as she found this to sound very negative. She
explained that if the result is a 100% certain, this takes her
hope away that her situation can still turn out positively.
Expected Reactions after Receiving a Positive Brain
Amyloid PET Scan
We asked participants how they thought they would
respond if they were to receive a positive PETscan result,
implying the chances were high that in a few years they
might convert to AD. Different responses, depending on
the coping strategy of the participants, emerged. For some
participants, they stated that it was difficult to anticipate
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how they would respond to this news, whilst others had
no difficulties and immediately indicated that they would
be emotional, leading to tears, or that this news could
have a negative impact on their state of mind. Some
participants indicated that they would feel somehow
shocked after receiving this news. As one participant
described it: BYes, certainly a bit shocked, because you
always expect that you won’t get it^ (Woman, 68 years
old). As some participants presume they will receive
good news, others assume, or are convinced, that they
already have AD: BSad. Although I realize that I’m
regressing, I know it^ (Woman, 81 years old). Others
saw a positive PET scan result as a confirmation of their
current memory problems they are experiencing.
Most participants reacted to a positive result by
responding in a solution-oriented way, which was
interpreted in a broad sense by them. More specifically,
they imagined solutions ranging from starting therapy to
making lifestyle changes to making practical arrangements.
While most participants described their own reaction
to the disclosure of a positive result, some participants
were more concerned about their partner’ and children’s
reaction:
BI would find that very bad for my wife, for my
children, for myself also, but yes, for myself, for
myself I would find that rather sad. Do you un-
derstand the difference?^ (Man, 67 years old).
Although most participants indicated that a positive
brain amyloid PET scan is unpleasant news to receive,
they concluded that it is better to receive this news rather
than to know nothing and have lingering doubt about
their own health situation. One participant indicated that
it was better to receive a positive result rather than a
negative result:
B[...] then you’ve got something to plan for and
you’ve got something, you know. Because it’s
sometimes more worrying than if they say there
is nothing there, because then, what’s my problem
due too?^ (Man, 66 years old).
Expected Reactions after Receiving a Negative Brain
Amyloid PET Scan
Patients’ reactions to a negative brain amyloid PET scan
result were less diverse and can be clustered into two
types of hypothetical reactions. On the one hand, some
participants were happy and relieved after receiving a
negative result. These participants responded either ex-
tremely enthusiastically: BThank you! Well, is there any
champagne? [laughs][...]^ (Man, 80 years old). Whilst
others responded more subtly: BRelieved, logically […].
But still, yes, I would keep in the back of my mind that,
[inarticulate] it eventually is still possible to happen in
the far future. Maybe I’m already gone by then^ (Man,
73 years old).
On the other hand, many participants were left with
the question: BWhat is causing my symptoms?^ This
lead to questioning the value of the result or of further
investigation:
BYes, then I would ask myself, how it is that I’m
forgetting that much [laughs]. I would ask: ‘Is
everything correct?’^ (Man, 67 years old).
Discussion
In this study, we sought to document and better under-
stand the reasons why aMCI patients participating in a
research study were either in favor of or against the
disclosure of their individual brain amyloid PET scan
results and what advantages/disadvantages they per-
ceived about IRR disclosure/non-disclosure. The two
most frequently mentioned reasons for choosing IRR
disclosure were to better understand their own brain
health status and to be able to make informed decisions
about future personal arrangements they might have to
make if their PET scans were consistent with the devel-
opment of AD. Emotional risk was mentioned as the
primary disadvantage of knowing one’s IRR.
In the field of AD research, not a lot of research on
brain amyloid IRR disclosure has been done. However, a
number of studies focused in particular on the desire of
participants to opt for genetic AD risk assessment
[16–18]. For example, a telephone survey in a
community-recruited sample concluded that 79% of re-
spondents expressed interest in predictive genetic testing
for AD [18]. Another recent survey in cognitively normal
older adults by Gooblar et al. indicated that 97% of
participants had a strong interest in obtaining their re-
search results, including those related to the detection of
the molecular pathology of AD, such as amyloid imaging
[19]. In all previously mentioned studies only a minority
of participants preferred not to know their IRR. In our
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study, all 38 of the aMCI patients (i.e., 100% of partici-
pants) wanted to know their brain amyloid IRR. Our
sample was quite diverse demographically, varying in
age from 55 to 83 years (mean 71 years; 58%men), most
being married with children, and most finishing second-
ary school or higher. An important limitation is that all 38
aMCI patients were recruited via the memory clinic and
already took first initiative to receive medical advice.
Although all of our participants wanted to know
their IRR, two caveats should be mentioned about
these results. One participant initially did not want
to know his IRR but later on changed his mind.
Another participant stated that he did not want to
know his IRR but said that his wife really wanted to
know. In this case, we explained to him and his wife
together what this would mean practically and how
they might deal with the situation in which one
spouse knew the results and the other did not. With
additional time to reflect, this participant decided
that he wanted to know the results. We carefully
queried this participant’s reasoning to determine
whether he was Bpushed^ into his decision for IRR
disclosure by his wife, or whether he made the
decision independently.
This high percentage of aMCI patients wanting to
receive their IRR suggests that in the near future
more participants might be open to participating in
research if they have the possibility of receiving
their IRR. However, researchers should be aware
that if the release of IRR to subjects and patients
were to become commonplace, it might attract peo-
ple with subjective mental complaints or hypochon-
driacs to volunteer for research studies, which would
then negatively affect not only recruiting criteria and
the recruiting process but also research results. Thus,
more research is needed on how participants might
volunteer for a clinical trial, but opt out of receiving
their IRR. Although in most studies, this group is
smaller than the group of participants who do want
to know, insight into the opinions and perspectives
of the people who opt out of wanting to know is
equally important for the IRR disclosure/non-
disclosure debate.
The predictive value of brain amyloid PET scans of
aMCI patients for progression to AD in the next years
has certain limitations. This is an ethical issue being
debated in the general literature about IRR disclosure
[20–22] and is a point highlighted in our information
brochure. Our hypothesis was that the limitations of the
predictive value of brain amyloid PET scans would be
perceived as a disadvantage by participants for wanting
to know this particular type of IRR. No participants
mentioned this as a disadvantage, even though they
presumably read about it in the brochure. To temper
the possibility that participants were providing socially
desirable answers, we asked more in-depth follow-up
questions about this limited predictive value. Still, it was
clear that participants did not perceive this as a disad-
vantage. Participants with aMCI still perceived that it
was better to know if they had a high or low risk of
developing AD than to remain completely Bin the dark^
about their current health situation. In addition, our
results indicate how some participants perceived this
uncertainty as a positive aspect, since it leaves open
the possibility for hope. Nevertheless, accurate and clear
information about IRR and its associated limited predic-
tive value remains important in order to prevent patients
from misunderstanding this information.
Another hypothesis we had was that participants
would mention the limited efficacy of current treat-
ment options as a disadvantage of knowing their IRR.
This hypothesis was based on published reports sug-
gesting that available treatment options are perceived
as an ethical issue [8, 20, 22]. This was not mentioned
as a disadvantage by any of our participants. When
asked, participants answered that they already knew
before the start of the study that there is no cure
available for AD, or that there is medication available
but that it can only delay progression of the disease.
The latter was perceived as a better option than receiv-
ing no medication at all. Some participants referred to
the situation of cancer and its treatment, in which
medicine can already do a lot, but is not always able
to cure the disease. Most participants maintained
strong hope that in the near future the situation will
change for early treatment of AD, whereby re-
searchers can rapidly make medical progress.
The concept of therapeutic misconception is important
to consider when trying to understand participants’ deci-
sions in choosing disclosure/non-disclosure of IRR. This
concept, which is often mentioned by the general literature
about IRR disclosure [5, 6, 23, 24], refers to the situation
in which patients often fail to distinguish between clinical
care and the research setting. Participants believe the
researcher is a physician who has two core ethical obliga-
tions: (1) endeavor to avoid non-maleficence (no harm),
and (2) work toward beneficence (doing well). BDoing
well^ can be understood as taking care of the health and
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well-being of the patient by providing necessary therapy
and drug treatments [23, 25]. In this case, patients who
become participants in clinical trials often expect or have
high hopes that they will receive treatment. As described
in our findings, participants do perceive the option for
treatment as a reason to know their IRR. Thus, the thera-
peutic misconception also occurred in our study. Two
nuances should be addressed.
First, described in the informed consent brochure
as mandatory by the International Guidelines of
Good Clinical Practice (ICH GCP) [26] and ex-
plained by our researchers to the study participant,
was that participants would receive cholinesterase
inhibitors if they had a positive amyloid PET scan.
Thus, this knowledge likely would affect a partici-
pant’s decision about IRR disclosure. For a negative
amyloid PET scan, this medication would not be
prescribed, because it is less effective when the
underlying pathology is not related to AD. Second,
the concept of treatment was interpreted widely by
participants and was not limited to medication. Fol-
low-up, disease monitoring, and imposition of
health-related life style changes (e.g., taking food
supplements, cessation of drinking, etc.) were also
thought of as treatment. This broad understanding
also likely affected participants’ decisions about
IRR disclosure.
The majority of our participants reflected on plan-
ning for the future as an advantage of knowing their
IRR. This finding is in line with other AD studies,
such as the Risk Evaluation and Education for
Alzheimer’s Disease study (REVEAL) who reported
on the importance of making arrangements for the
future [16, 27, 28]. In our study, almost one-in-five
participants also mentioned end-of-life decisions as
playing a prominent role in their reasoning about
IRR, more specifically the request for euthanasia,
given a positive brain amyloid result. The partici-
pants who mentioned this possibility in our study
might have been influenced by ongoing legal dis-
cussions in Belgium. First since 2002, euthanasia
can be legally requested in Belgium under strict
circumstances (Belgian Euthanasia Act, 28th of
May 2002) [29]. These circumstances, imply that:
(1) the patient is legally competent and conscious at
the moment of making the request; (2) the request is
voluntary, well-considered and repeated, and is not
the result of any external pressure; (3) the patient is
in a medically futile condition of constant and
unbearable physical or mental suffering that cannot
be alleviated, resulting from a serious and incurable
disorder caused by illness or accident (section 3, §1)
[29]. Second in past years, there has been a growing
awareness in Belgium that healthcare institutions
bear the responsibility for translating these legal
regulations into optimal care for patients requesting
euthanasia. For example, enhancing communication
toward patients and their relatives about end-of-life
decisions and early care planning [30, 31]. To prop-
erly compare the situation in Belgium with that in
other countries, research is needed to evaluate
whether euthanasia might be considered as a reason
for wanting to know one’s IRR, and if this would
lead to an increase in euthanasia requests.
aMCI participants in our study mentioned euthanasia
as a practical arrangement; two ethical concerns
emerged from this. First, most participants explained
how they do not want to become a burden to their family
members. Thus, euthanasia was perceived as a solution,
whereby family members would not be burdened with a
beloved one who has AD. A person’s source of Bburden
awareness^ is an important consideration: In a euthana-
sia request, did the patient independently arrive at the
awareness that he may become a burden, or did he
become aware of it by discussions with relatives? Ac-
cording to the Belgian Act on Euthanasia, the request
needs to be voluntary, well considered, and not the result
of any external pressure [29].
Although there is a worldwide increase in the
burden of caring for people with dementia, the so-
lution for this problem should not be euthanasia but
proper help throughout the care process from the
perspective of both patients and caregivers. Govern-
ment and healthcare regulations ought to (a) invest
in damping down the perception that patients feel
they are or will become a burden to their family
members and in lifting the actual burden family
members currently experience; and (b) maximize
proper care that enhances the capabilities of patients
and provide respite to ensure that the life of care-
givers is not put Bon hold^ because they are provid-
ing care for their beloved one with dementia.
A second ethical concern that relates to aMCI partic-
ipants in our study mentioning euthanasia as a practical
arrangement is that participants feared living in a vege-
tative state, not wanting to Bend up living like a plant.^
This indicates how there is a negative perception or
stigma about AD. Only one participant indicated that
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having AD does not necessarily mean that they will be
living in an unhappy world.
Our findings also reveal how our participants are
unclear about the legislation on end-of-life decisions in
Belgium. This resulted in the use of the term euthanasia
in general terms and showed that they were unaware of
the different types of documents Belgian legislation
provides. In Belgium, there are five different documents
regarding advanced-care planning and end-of-life deci-
sions [32]. Three of these documents are important, and
our participants appear to be confused about them. The
first one addresses negative advance declaration about
the refusal of certain treatment options; the second ad-
dresses the stipulation that advance declaration regard-
ing euthanasia is a document that has to be prepared in
advance and has to be renewed every five years. Eutha-
nasia will only be performed in case of irreversible
coma, which excludes dementia. The third ad-
dresses an active request for euthanasia [32]. The
above-mentioned criteria of the Belgian Euthanasia
Act also need to be followed. It is clear that our
participants confuse issues germane to these three
documents. Many participants think that the ad-
vance declaration regarding euthanasia is sufficient
if they receive an AD diagnosis. In reality, if a
patient with an AD diagnosis wants euthanasia to
be performed, he has to declare an active request
for euthanasia at the earliest stage of the disease
when he is still capable of expressing his wishes.
This implies that the patient actively chooses to
shorten his life by certain good months/years be-
fore cognitive deterioration becomes worse.
There was also confusion among some partici-
pants about the terminology used for positive and
negative amyloid PET scans. Some patients under-
stood a positive scan to be good news, a report
with a favorable outcome for future brain health.
Although the correct terminology was explained in
the informed consent brochure and throughout the
information session when the researcher explained
the content of the trial face-to-face with the pa-
tient, we noticed that throughout the interviews,
patients misused or misunderstood the terminology.
If the interviewer noticed that a participant misun-
derstood the terminology, she elaborated on the
point with the aim of avoiding the situation in
which the interviewee and interviewer were talking
about Bdifferent^ results. Thus to clarify the termi-
nology, we compared the amyloid test to an
alcohol test: Having too much alcohol in the blood
results in a positive alcohol test. In the same way,
having too many amyloid plaques in your brain
results in a positive amyloid test. Most of our
participants understood this comparison. For pa-
tients to understand this type of research result, it
is imperative to explain it clearly in a simple and
correct way.
Limitations
The current study aimed to gain insight into the motiva-
tions and opinions of patients with regard to the disclo-
sure IRR of brain amyloid PET scans in a research
context. The strength of this qualitative sub-study
was its in-depth patient interviews, which enabled
us to better understand their motivations, opinions,
and experiences. Face-to-face interviews provide
researchers the opportunity to go beyond numerical
quantitation, which can overlook the real reasons
behind a subject’s answers; interviews allow re-
searchers to get a correct understanding of the
interviewee’s opinions [33]. A limitation with all
qualitative research, however, is that participants
are always embedded in a certain cultural or soci-
etal setting, which can influence the results [33].
For example, the widely discussed views on eu-
thanasia in Belgium could have affected our re-
sults. The views of participants presented here are
based on a small population of aMCI patients in Bel-
gium who were recruited via the UZ Leuven memory
clinic. It is possible that somewhat different findings
may emerge when investigating this topic in a different
country or when recruiting a different study population.
For example, subjects with minor memory complaints
who have not undertaken the first steps to receive med-
ical advice from the memory clinic or healthy adults
being evaluated for preclinical AD. We do believe that
the findings are important beyond the context of this
research and can be of use for further clinical trials.
Conclusion
Overall, this study showed that aMCI patients have
clear motivations on why they want to know their
brain amyloid IRR and what they perceive as
advantages/disadvantages of knowing their IRR.
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The most frequently mentioned benefits were to
achieve clarity regarding their deteriorating health,
to start informed treatment options, and to plan for
the future by making informed decisions about cer-
tain arrangements that may be required. Most of the
participants mentioned the emotional risk as the main
disadvantage, although most thought they would be
able to cope with receiving bad news about a pos-
itive scan. The limited efficacy of current treatment
options and the limited predictive value of the amy-
loid PET scan were not perceived as disadvantages.
This latter outcome highlights that patients’ interpre-
tation of what is written in the informed consent as
possible risks and benefits can differ from what was
intended by researchers.
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Appendix
Appendix 1 Inclusion and exclusion criteria for the BioAdaptAD study
Inclusion criteria Exclusion criteria
Patients must meet all of the following inclusion criteria
to participate in the study:
• Patient is male or female and 55 – 85 years of age on
the day of signing the consent form.
• If female, patient lacks reproductive potential
(two years post-menopausal or surgically sterile).
• Patient has a subjective memory concern, as reported
by subject, study partner, or clinician.
• Patient has abnormal memory function documented by
scoring below the criteria on the indicated cognitive exams:
Education-adjusted ranges on the AVLT total
learning or delayed recall percentage (≥ −1SD).
• Patient has a Global Clinical Dementia Rating
score of 0 or 0.5.
• In the opinion of the investigator, the patient is in stable medical
condition and is willing and able to perform study procedures.
Patients will be ineligible for participation in this study if
they meet any of the following exclusion criteria:
- Patient has a history or current evidence of a neurological
disorder that, in the opinion of the primary investigator,
may contribute to the subject’s cognitive impairment.




• progressive supranuclear palsy
• Huntington’s disease
• amyotrophic lateral sclerosis
• multiple sclerosis
• CNS infection
• significant head trauma with loss of consciousness
• normal pressure hydrocephalus
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